Targeted Oncology1d
Evaluating Fedratinib in Rare Myeloproliferative Diseases
Andrew Kuykendall, MD, discusses the rationale behind choosing to evaluate fedratinib in a phase 2 study for patients with atypical chronic myeloid leukemia, chronic neutrophilic leukemia, ...
Taiwan News1d
ORYZON announces first patient dosed in an Investigator-initiated Phase I study of iadademstat in myelodysplastic syndrome
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...
Alzheimer's Disease Therapeutics Market Size In The 7MM Was ~USD 3,610 Million In 2023 And Is Expected To Grow By 2034
Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...
Targeted Oncology4d
Fedratinib Shows Promise in Chronic Neutrophilic Leukemia and MDS/MPN
In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...
The American Journal of Managed Care6d
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...